Patents Assigned to Pfizer
  • Patent number: 5106614
    Abstract: A bone cement is disclosed wherein the liquid component contains a therapeutic or diagnostic substance in combination with an emulsifying agent for said substance.
    Type: Grant
    Filed: December 18, 1989
    Date of Patent: April 21, 1992
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventors: Jessica Posey-Dowty, Paul A. Higham, Nestor A. Arroyo, Casper F. Stark
  • Patent number: 5104868
    Abstract: This invention relates to novel tricyclic derivatives of 7-substituted-6-fluoro-1,4-dihydroquinol-4-one-3-carboxylic acids and certain esters and cation salts thereof. The compounds of this invention are substituted at the 7-position by vinyl, W--CH.dbd.CH--, CH.sub.3 C.tbd.C--, W--CH.sub.2 C.tbd.C-- or ##STR1## where W is selected from certain substituted alkyl groups. This invention also relates to antibacterial compositions containing the compounds and methods of using the compounds to treat bacterial disease.
    Type: Grant
    Filed: August 29, 1990
    Date of Patent: April 14, 1992
    Assignee: Pfizer Inc.
    Inventor: Paul R. McGuirk
  • Patent number: 5104874
    Abstract: A series of 2-amino-5,6-dimethyl-1,4-benzoquinone derivatives, inhibitors of cyclooxygenase and lipoxygenase and useful as antiallergic and antiinflammatory agents.
    Type: Grant
    Filed: December 13, 1990
    Date of Patent: April 14, 1992
    Assignee: Pfizer Inc.
    Inventors: Takafumi Ikeda, Hiroaki Wakabayashi, Masami Nakane
  • Patent number: 5103040
    Abstract: This invention relates to novel 1,7-disubstituted-6-fluoro-1,4-dihydroquinol-4-one-3-carboxylic acid derivatives and certain esters and cation salts thereof. This invention further relates to preparation of the compounds, antibacterial compositions containing the compounds and methods of using the compounds.This invention also relates to a novel process for preparing novel N-cyclopropyl intermediates useful for preparing certain of the 1,7-disubstituted-6-fluoro-1,4-dihydroquinol-4-one-3-carboxylic acid derivatives of this invention which contain a cyclopropyl substituent at the 1 position as well as other 1,4-dihydroquinol-4-one-3-carboxylic acid derivatives so substituted with cyclopropyl.
    Type: Grant
    Filed: May 29, 1991
    Date of Patent: April 7, 1992
    Assignee: Pfizer Inc.
    Inventor: Paul R. McGuirk
  • Patent number: 5100407
    Abstract: A multi-piece trial femoral component kit is used for preparing and sizing a femoral cavity prior to implantation of a prosthetic femoral component. The trial component kit has at least three trial stem portions of differing size and at least three trial body portions of different size. The stem and body portions include mating male and female elements which allow the stem portions to be securely coupled to the body portions. In order to ensure that the so-coupled stem and body portions form a trial femoral component having a size equal to an available orthopedic femoral implant, the male and female elements include a key and keyway which are sized so that only trial stem and body portions resulting in an available femoral implant can be combined and used as a trial femoral component.
    Type: Grant
    Filed: September 4, 1990
    Date of Patent: March 31, 1992
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventors: Gordon C. Conrad, Thomas J. Parchinski
  • Patent number: 5100785
    Abstract: A new acidic polycyclic ether antibiotic UK-58,852 has the formula: ##STR1## wherein R and R.sup.1 are both hydrogen, and can be prepared by the submerged aerobic propagation in aqueous nutrient media of Actinomadura sp. ATCC 39697. The antibiotic and its cationic salts are active against a variety of microorganisms and are effective in controlling coccidiosis, enteritis, swine dysentery and theileriosis as well as being effective in promotion of growth and/or improving efficiency of feed utilization in swine and ruminants. Two minor components, wherein R is H and R.sup.1 is CH.sub.3 and wherein R and R.sup.1 are both CH.sub.3, have also been isolated from the fermentation.
    Type: Grant
    Filed: December 17, 1990
    Date of Patent: March 31, 1992
    Assignee: Pfizer Inc.
    Inventors: Walter P. Cullen, Hiroshi Maeda, John C. Ruddock, Junsuke Tone
  • Patent number: 5100648
    Abstract: A composition for cleaning the gums comprising silica, water and a detergent, said composition having a RDA of less than 20.
    Type: Grant
    Filed: July 1, 1991
    Date of Patent: March 31, 1992
    Assignee: Pfizer Inc.
    Inventors: Athanasios S. Ladas, Debbie L. Burnett-Davis, Ronald J. Sharpe, Suzanne H. Ispentchian
  • Patent number: 5097653
    Abstract: A verification system for detecting the presence and absence of an object includes a verification station. A preselected number of objects is delivered to the verification station with each object disposed at a selected position. A pneumatic comparator is located at each selected position. Each pneumatic comparator comprises a head directed toward its corresponding selected position. The head includes an exit port and an entry port whereby air may be discharged through the exit port and directed toward the selected position. If an object is located at the selected position the air is reflected back into the entry port where it is sensed to indicate the presence of the object.
    Type: Grant
    Filed: December 27, 1990
    Date of Patent: March 24, 1992
    Assignee: Pfizer Inc.
    Inventor: Sabrie B. Soloman
  • Patent number: 5098437
    Abstract: An acetabular cup for use as a prosthetic implant has an insert with a body including a central bore for receiving a positioning rod therein. A key element is formed on the bore and is adapted to align the positioning rod. The insert has a locating element formed on an outer surface of the body and also includes spring elements extending radially outwardly from the body. The acetabular cup has a generally hemispherical shell member coupled to the outer surface of the insert. The shell has an outer surface for engaging the acetabulum and an inner surface having a circumferential groove for receiving the spring elements. The spring elements may be deflected radially inwardly out of engagement with the groove for releasing the insert from the shell. The shell has a plurality of apertures extending from its inner to its outer surface, which apertures are located in an asymmetrical pattern about the shell.
    Type: Grant
    Filed: February 13, 1991
    Date of Patent: March 24, 1992
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventors: Glen A. Kashuba, Jon I. Klippel
  • Patent number: 5096890
    Abstract: Compounds of the formula ##STR1## wherein R, Y and R.sup.1 are as defined in the specification. These compounds are muscarinic receptor antagonists which are selective for smooth muscle muscarinic sites over cardiac muscarinic sites, and are useful in the treatment of diseases associated with altered motility on tone of smooth muscle, including irritable bowel syndrome, diverticular disease, urinary incontinence, oesophageal achalasia and chronic obstructive airways disease.
    Type: Grant
    Filed: March 13, 1990
    Date of Patent: March 17, 1992
    Assignee: Pfizer Inc.
    Inventors: Peter E. Cross, Alexander R. MacKenzie
  • Patent number: 5095121
    Abstract: 1S,4S and 1R,4R-2-Alkyl-2,5-diazabicyclo[2.2.1]heptanes useful as intermediates in the synthesis of certain antibacterial quinolones, are prepared respectively, from trans-4-hydroxy-L-proline and trans-4-hydroxy-D-proline via multistep procedures.
    Type: Grant
    Filed: January 8, 1991
    Date of Patent: March 10, 1992
    Assignee: Pfizer Inc
    Inventors: Tamim F. Braish, Darrell E. Fox
  • Patent number: 5095127
    Abstract: A new acidic polycyclic antibiotic UK-61,689 has the formula: ##STR1## or a pharmaceutically acceptable cationic salt thereof. The antibiotic and its cationic salts are active against a variety of microorganisms and are effective in controlling coccidiosis, enteritis and swine dysentery as well as being effective in promotion of growth and/or improving efficiency of feed utilization in swine and ruminants.
    Type: Grant
    Filed: December 17, 1990
    Date of Patent: March 10, 1992
    Assignee: Pfizer Inc.
    Inventors: Alexander C. Goudie, Nigel D. A. Walshe
  • Patent number: 5093319
    Abstract: A method for preventing adhesion between vital tissues includes the step of placing between the tissues a material made up of biodegradable derivatives of chitin which are soluble in aqueous solutions containing dilute acids such as acetic acid. This material has the advantage of requiring no reoperation for its removal since it would be degraded and absorbed after completing its function in vivo. These materials may be in the form of a visco-elastic fluid, a gel, a film or a membrane.
    Type: Grant
    Filed: January 24, 1991
    Date of Patent: March 3, 1992
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventors: Paul A. Higham, Jessica D. Posey-Dowty
  • Patent number: 5091383
    Abstract: Antibacterial compounds have the formula ##STR1## wherein R.sup.1 is hydrogen, a pharmaceutically acceptable cation, or alkyl; A is CH, CF, CCl or N; Y is alkyl, haloalkyl, cyclopropyl, vinyl, methoxy, N-methylamino, p-fluorophenyl, p-hydroxyphenyl or p-aminophenyl; or A is carbon and is taken together with Y and the carbon and nitrogen to which A and Y are attached to form a five to seven membered ring which is optionally substituted; and R.sup.2 is a bridged-diazabicycloalkyl group.
    Type: Grant
    Filed: February 16, 1988
    Date of Patent: February 25, 1992
    Assignee: Pfizer Inc.
    Inventors: Martin R. Jefson, Paul R. McGuirk
  • Patent number: 5089514
    Abstract: Certain 3-(phenyl, chroman-2-yl, benzofuran-5-yl, or benzoxazol-5-yl)-2-(hydroxy or mercapto)propionic acid derivatives and analogs are useful as hypoglycemic and hypocholesterolemic agents.
    Type: Grant
    Filed: June 14, 1990
    Date of Patent: February 18, 1992
    Assignee: Pfizer Inc.
    Inventor: Bernard Hulin
  • Patent number: 5089505
    Abstract: A series of novel 1-(phenethyl) and 1-(1-heteroarylethyl)-3-substituted piperidine derivatives have been prepared, including their pharmaceutically acceptable salts and various novel key intermediates therefor. The 3-substituent present in these compounds is an unsubstituted or substituted diphenylmethoxy group or a diphenylmethoxy-derived group, while the 1-substituent is unsubstituted or substituted phenethyl or 1-(2-heteroarylethyl) wherein the heteroaryl moiety is thienyl, pyridyl or pyrazinyl. These compounds in the form of both their racemates and 3R-isomers, are useful in therapy as smooth muscle muscarinic receptor antagonists and therefore, are of value in the treatment diseases associated with altered motility and/or smooth muscle tone. The most preferred compound is (3R)-diphenylmethoxy-1-(3,4-methylenedioxyphenethyl)piperidine. Methods for preparing these compounds from known starting materials are provided.
    Type: Grant
    Filed: July 6, 1989
    Date of Patent: February 18, 1992
    Assignee: Pfizer Inc.
    Inventors: David Alker, Peter E. Cross, Robert M. Wallis
  • Patent number: 5089480
    Abstract: The invention provides novel compounds having the formula: ##STR1## wherein R when taken individually is H; R.sup.1 when taken individually is H or OH; R and R.sup.1 when taken together represent a double bond;R.sup.2 is an alpha-branched C.sub.3 -C.sub.8 alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group; a C.sub.3 -C.sub.8 cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl or C.sub.5 -C.sub.8 cycloalkylalkyl group, any of which may be substituted by methylene or one or more C.sub.1 -C.sub.4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be substituted by one or more C.sub.1 -C.sub.4 alkyl groups or halo atoms;R.sup.3 is hydrogen or methyl;R.sup.4 is H or 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy with the proviso that when R.sup.2 is alkyl it is not isopropyl or sec-butyl; when R.sup.4 is H, each of R and R.sup.1 is H, and R.sup.2 is not methyl or ethyl; and when R.sup.4 is H, R is H, R.sup.1 is OH, and R.sup.
    Type: Grant
    Filed: January 11, 1988
    Date of Patent: February 18, 1992
    Assignee: Pfizer Inc.
    Inventors: Stephen P. Gibson, Alexander C. Goudie, Kelvin S. Holdom, John D. Bu'lock
  • Patent number: 5089637
    Abstract: Optically active (C.sub.1 -C.sub.3) alkyl 2R-chroman-2-carboxylates are prepared by partial hydrolysis of the corresponding racemic ester using a microbial lipase as catalyst. Said 2R-chromancarboxylate is converted via novel 2R-(hydroxymethyl) chroman, 2R-(trifluoromethylsulfonyloxymethyl) chroman and 2R-benzylchroman intermediates into 2R-benzylchroman-6-carbaldehyde, a compound of known utility in the manufacture of certain hypoglycemic agents.
    Type: Grant
    Filed: March 21, 1990
    Date of Patent: February 18, 1992
    Assignee: Pfizer Inc.
    Inventor: Frank J. Urban
  • Patent number: 5087732
    Abstract: The invention provides the substantially optically pure 2(S)-stereoisomeric form of compounds of the formulae: ##STR1## and the salts thereof, together with processes for their preparation. The compounds are intermediates for the preparation of antihypertensive agents.
    Type: Grant
    Filed: October 26, 1990
    Date of Patent: February 11, 1992
    Assignee: Pfizer Inc.
    Inventors: Ian T. Barnish, Keith James
  • Patent number: D324102
    Type: Grant
    Filed: September 27, 1988
    Date of Patent: February 18, 1992
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventors: Quinton J. Farrar, Frederick A. Everett, Jr., Richard H. Heimann